FDMT · 4D Molecular Therapeutics, Inc.
Price & Indicators
Latest filings
4D Molecular Therapeutics said the first patients were enrolled across multiple sites in the 4SIGHT Phase 3 trial of 4D-150 for diabetic macular edema. Two-year SPECTRA data showed a 61% overall treatment-burden reduction for the Phase 3 dose.
Read the 8-KMetrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Revenue from clinical trials and other studies performance obligations (Otsuka) | $3.7M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FDMT
this stock
4D Molecular Therapeutics, Inc.
|
$863.27M | +72.4% | +230194.6% | — | 16.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$134.22B | +16.8% | +46.2% | 30.8 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.02B | +5.4% | +20.8% | 20.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +626.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Sep 28, 2026
- This year
- 24
4D Molecular Therapeutics said the first patients were enrolled across multiple sites in the 4SIGHT Phase 3 trial of 4D-150 for diabetic macular edema. Two-year SPECTRA data showed a 61% overall treatment-burden reduction for the Phase 3 dose.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FDMT | +2.5% | -9.6% | +30.2% | -9.6% | +72.4% |
| SPY | -0.1% | +1.3% | +5.6% | +1.3% | +13.3% |
| vs SPY | +2.6% | -10.9% | +24.6% | -10.9% | +59.1% |